| Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial AB El-Khoueiry, B Sangro, T Yau, TS Crocenzi, M Kudo, C Hsu, TY Kim, ... The Lancet 389 (10088), 2492-2502, 2017 | 3930 | 2017 |
| Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade PJ Johnson, S Berhane, C Kagebayashi, S Satomura, M Teng, ... Journal of Clinical Oncology 33 (6), 550, 2015 | 2190 | 2015 |
| BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update M Reig, A Forner, J Rimola, J Ferrer-Fàbrega, M Burrel, Á Garcia-Criado, ... Journal of hepatology 76 (3), 681-693, 2022 | 1853 | 2022 |
| Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy M Reig, Z Mariño, C Perelló, M Iñarrairaegui, A Ribeiro, S Lens, A Díaz, ... Journal of hepatology 65 (4), 719-726, 2016 | 1030 | 2016 |
| A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C B Sangro, C Gomez-Martin, M de la Mata, M Iñarrairaegui, E Garralda, ... Journal of hepatology 59 (1), 81-88, 2013 | 1024 | 2013 |
| Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial T Yau, YK Kang, TY Kim, AB El-Khoueiry, A Santoro, B Sangro, I Melero, ... JAMA oncology 6 (11), e204564-e204564, 2020 | 902 | 2020 |
| Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up A Vogel, A Cervantes, I Chau, B Daniele, JM Llovet, T Meyer, JC Nault, ... Annals of oncology 29, iv238-iv255, 2018 | 861 | 2018 |
| CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular … T Yau, JW Park, RS Finn, AL Cheng, P Mathurin, J Edeline, M Kudo, ... Annals of Oncology 30, v874-v875, 2019 | 734 | 2019 |
| Advances in immunotherapy for hepatocellular carcinoma B Sangro, P Sarobe, S Hervás-Stubbs, I Melero Nature reviews Gastroenterology & hepatology 18 (8), 525-543, 2021 | 731 | 2021 |
| Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions L Bolondi, A Burroughs, JF Dufour, PR Galle, V Mazzaferro, F Piscaglia, ... Seminars in liver disease 32 (04), 348-359, 2012 | 713 | 2012 |
| Survival after yttrium‐90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation B Sangro, L Carpanese, R Cianni, R Golfieri, D Gasparini, S Ezziddin, ... Hepatology 54 (3), 868-878, 2011 | 695 | 2011 |
| Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors B Sangro, G Mazzolini, J Ruiz, M Herraiz, J Quiroga, I Herrero, A Benito, ... Journal of clinical oncology 22 (8), 1389-1397, 2004 | 694 | 2004 |
| Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization JL Raoul, B Sangro, A Forner, V Mazzaferro, F Piscaglia, L Bolondi, ... Cancer treatment reviews 37 (3), 212-220, 2011 | 657 | 2011 |
| Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial T Yau, JW Park, RS Finn, AL Cheng, P Mathurin, J Edeline, M Kudo, ... The Lancet Oncology 23 (1), 77-90, 2022 | 641 | 2022 |
| Pikarsky Eet al. et al JM Llovet, J Zucman-Rossi Hepatocellular carcinoma. Nature Reviews Disease Primers 2, 16018, 2016 | 610* | 2016 |
| Immunological landscape and immunotherapy of hepatocellular carcinoma J Prieto, I Melero, B Sangro Nature reviews Gastroenterology & hepatology 12 (12), 681-700, 2015 | 552 | 2015 |
| New therapies for hepatocellular carcinoma MA Avila, C Berasain, B Sangro, J Prieto Oncogene 25 (27), 3866-3884, 2006 | 512 | 2006 |
| Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma GK Abou-Alfa, G Lau, M Kudo, SL Chan, RK Kelley, J Furuse, ... NEJM evidence 1 (8), EVIDoa2100070, 2022 | 506 | 2022 |
| Liver disease induced by radioembolization of liver tumors: description and possible risk factors B Sangro, B Gil‐Alzugaray, J Rodriguez, I Sola, A Martinez‐Cuesta, ... Cancer 112 (7), 1538-1546, 2008 | 404 | 2008 |
| Radioembolization for hepatocellular carcinoma B Sangro, M Iñarrairaegui, JI Bilbao Journal of hepatology 56 (2), 464-473, 2012 | 375 | 2012 |
